AU2016307430B2 - Anti-ANGPTL8 antibodies and uses thereof - Google Patents

Anti-ANGPTL8 antibodies and uses thereof Download PDF

Info

Publication number
AU2016307430B2
AU2016307430B2 AU2016307430A AU2016307430A AU2016307430B2 AU 2016307430 B2 AU2016307430 B2 AU 2016307430B2 AU 2016307430 A AU2016307430 A AU 2016307430A AU 2016307430 A AU2016307430 A AU 2016307430A AU 2016307430 B2 AU2016307430 B2 AU 2016307430B2
Authority
AU
Australia
Prior art keywords
artificial sequence
ser
antibody
gly
angptl8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016307430A
Other languages
English (en)
Other versions
AU2016307430A1 (en
Inventor
David R. Buckler
Jesper Gromada
Viktoria Gusarova
Andrew J. Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2016307430A1 publication Critical patent/AU2016307430A1/en
Application granted granted Critical
Publication of AU2016307430B2 publication Critical patent/AU2016307430B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2016307430A 2015-08-07 2016-08-04 Anti-ANGPTL8 antibodies and uses thereof Ceased AU2016307430B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562202366P 2015-08-07 2015-08-07
US62/202,366 2015-08-07
PCT/US2016/045535 WO2017027316A1 (en) 2015-08-07 2016-08-04 Anti-angptl8 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2016307430A1 AU2016307430A1 (en) 2018-02-22
AU2016307430B2 true AU2016307430B2 (en) 2022-04-21

Family

ID=56979626

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016307430A Ceased AU2016307430B2 (en) 2015-08-07 2016-08-04 Anti-ANGPTL8 antibodies and uses thereof

Country Status (16)

Country Link
US (1) US10259870B2 (OSRAM)
EP (1) EP3331908B1 (OSRAM)
JP (2) JP7141333B2 (OSRAM)
KR (1) KR20180038020A (OSRAM)
CN (1) CN107922478A (OSRAM)
AR (1) AR105600A1 (OSRAM)
AU (1) AU2016307430B2 (OSRAM)
CA (1) CA2993976A1 (OSRAM)
EA (1) EA035088B1 (OSRAM)
ES (1) ES2870031T3 (OSRAM)
HK (1) HK1250238A1 (OSRAM)
IL (1) IL257263A (OSRAM)
MX (1) MX394103B (OSRAM)
TW (1) TW201713690A (OSRAM)
WO (1) WO2017027316A1 (OSRAM)
ZA (1) ZA201800352B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
HRP20230992T1 (hr) * 2016-02-17 2023-12-08 Regeneron Pharmaceuticals, Inc. Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3
MX2018010401A (es) 2016-03-03 2019-03-06 Regeneron Pharma Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
PL3439689T3 (pl) * 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
MX382035B (es) * 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
JP6853716B2 (ja) * 2017-03-31 2021-03-31 信越化学工業株式会社 レジスト下層膜材料、パターン形成方法、及びレジスト下層膜形成方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11434303B2 (en) 2017-06-28 2022-09-06 Bluefin Biomedicine, Inc. Anti-LY6H antibodies and antibody drug conjugates
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3749691A4 (en) * 2017-11-10 2021-10-27 NGM Biopharmaceuticals, Inc. ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
WO2019126194A1 (en) * 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
CN110613847B (zh) * 2019-10-23 2022-02-11 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN111135303A (zh) * 2020-01-17 2020-05-12 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US12391762B2 (en) 2020-08-26 2025-08-19 Twist Bioscience Corporation Methods and compositions relating to GLP1R variants
US20250188154A1 (en) * 2020-09-15 2025-06-12 Duke University Coronavirus antibodies and uses thereof
TWI833641B (zh) * 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
EP4594747A1 (en) * 2022-09-30 2025-08-06 9163-0384 Québec Inc Methods for the assessment of lipoprotein lipase deficiency and lipoprotein lipase bioavailability
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
CN119684452B (zh) * 2024-12-25 2026-03-27 中国药科大学 Angptl8中和性抗体在制备治疗细胞因子风暴综合征药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO1999040100A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US6956108B2 (en) 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
KR20100017169A (ko) 2007-05-22 2010-02-16 노파르티스 아게 Ｆｇｆ２１-관련 장애의 치료, 진단 및 검출 방법
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CN104039357A (zh) * 2011-06-10 2014-09-10 哈佛学院校长同事会 胰腺β-细胞增殖的调节
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP2804603A1 (en) * 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US20140178988A1 (en) * 2012-10-08 2014-06-26 Biotime, Inc. Differentiated Progeny of Clonal Progenitor Cell Lines
WO2014183207A1 (en) * 2013-05-17 2014-11-20 Exerkine Corporation Therapeutic method of treating metabolic syndrome
CN104164451A (zh) * 2014-08-09 2014-11-26 高连如 一种治疗2型糖尿病的基因工程干细胞
EP3822287A1 (en) * 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PL3439689T3 (pl) 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anonymous, "Product Data Sheet - Purified anti-Betatrophin (ANGPTL8)", (2014-07-25), BioLegend, URL: http://www.biolegend.com/pop_pdf.php?id=10113, (2016-11-08) *
Zhang Ren, ENDOCRINE SOCIETY'S 97TH ANNUAL MEETING AND EXPO, March 5-8, 2015 - SAN DIEGO, URL: http://press.endocrine.org/doi/10.1210/endo-meetings.2015.DGM.3.OR13-6, (2016-11-08) *

Also Published As

Publication number Publication date
CN107922478A (zh) 2018-04-17
MX2018001532A (es) 2018-03-15
KR20180038020A (ko) 2018-04-13
JP2021090449A (ja) 2021-06-17
WO2017027316A1 (en) 2017-02-16
MX394103B (es) 2025-03-24
US20170037124A1 (en) 2017-02-09
JP7141333B2 (ja) 2022-09-22
US10259870B2 (en) 2019-04-16
IL257263A (en) 2018-03-29
CA2993976A1 (en) 2017-02-16
EP3331908A1 (en) 2018-06-13
ZA201800352B (en) 2018-12-19
EP3331908B1 (en) 2021-03-10
JP2018525383A (ja) 2018-09-06
TW201713690A (zh) 2017-04-16
ES2870031T3 (es) 2021-10-26
EA201890453A1 (ru) 2018-07-31
EA035088B1 (ru) 2020-04-27
AR105600A1 (es) 2017-10-18
AU2016307430A1 (en) 2018-02-22
HK1250238A1 (zh) 2018-12-07

Similar Documents

Publication Publication Date Title
JP7500812B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
AU2020200892B2 (en) Anti-activin a antibodies and uses thereof
EP3331908B1 (en) Anti-angptl8 antibodies and uses thereof
KR101952786B1 (ko) 글루카곤 수용체에 대한 인간 항체
KR101859911B1 (ko) 사람 ｇｄｆ８에 대한 항체
AU2014241442B2 (en) Human antibodies to GREM 1
DK2721065T3 (en) Anti-ANGPTL3 antibodies and uses
DK2809681T3 (en) ANTI-ASIC1 antibodies and uses thereof
AU2017363143B2 (en) Methods of treating obesity with anti-ANGPTL8 antibodies
HUE031725T2 (en) High Human Human Protease Activated Receptor-2 Affinity
AU2013256251A1 (en) Human antibodies to Fel d1 and methods of use thereof
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
OA16261A (en) Antibodies to human GDF8.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired